| scholarly article | Q13442814 |
| P50 | author | Bettina M Jensen | Q89544602 |
| Dean D. Metcalfe | Q90856971 | ||
| Alasdair M Gilfillan | Q98184237 | ||
| Shoko Iwaki | Q114441406 | ||
| Michael A Beaven | Q114441411 | ||
| P2860 | cites work | Molecular regulation of mast cell activation | Q36496363 |
| Targeting kit activation: a potential therapeutic approach in the treatment of allergic inflammation | Q36757680 | ||
| EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation | Q40243206 | ||
| Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit | Q40263124 | ||
| Cutting Edge: Lentiviral short hairpin RNA silencing of PTEN in human mast cells reveals constitutive signals that promote cytokine secretion and cell survival | Q40290700 | ||
| Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis | Q40325513 | ||
| Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. | Q40442570 | ||
| The phospholipase C gamma 1-dependent pathway of Fc epsilon RI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase | Q40634199 | ||
| Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms | Q40672695 | ||
| Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. | Q40866333 | ||
| A comparison of mediators released or generated by IFN-gamma-treated human mast cells following aggregation of Fc gamma RI or Fc epsilon RI. | Q43545361 | ||
| Pathways of anaphylaxis in the mouse | Q43952644 | ||
| Determination of protein phosphorylation in Fc epsilon RI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions | Q44127938 | ||
| Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells | Q44951894 | ||
| Treatment of cockroach allergen asthma model with imatinib attenuates airway responses | Q45063930 | ||
| Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner | Q45168860 | ||
| Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930. | Q46644439 | ||
| PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects | Q46724516 | ||
| Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies | Q46882720 | ||
| Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma | Q52666713 | ||
| Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13) | Q73023303 | ||
| Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo | Q77399446 | ||
| The mastocyte: the "other" inflammatory cell in immunopathogenesis | Q80305936 | ||
| Btk plays a crucial role in the amplification of Fc epsilonRI-mediated mast cell activation by kit | Q81245378 | ||
| Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 | Q83862094 | ||
| Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor | Q24318673 | ||
| Development, migration, and survival of mast cells | Q24549674 | ||
| Structural mechanism for STI-571 inhibition of abelson tyrosine kinase | Q27627097 | ||
| Stem cell factor and its receptor c-Kit as targets for inflammatory diseases | Q28115994 | ||
| Early signaling pathways activated by c-Kit in hematopoietic cells | Q28139288 | ||
| NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation | Q28249353 | ||
| Mast cells | Q28253429 | ||
| Essential role for the p110delta phosphoinositide 3-kinase in the allergic response | Q28288981 | ||
| Essential role for Gab2 in the allergic response | Q28586578 | ||
| Chemistry and biology of resorcylic acid lactones | Q29039248 | ||
| Omalizumab-induced reductions in mast cell Fce psilon RI expression and function | Q33981258 | ||
| Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. | Q34414866 | ||
| A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. | Q34495587 | ||
| Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. | Q34573054 | ||
| The ins and outs of IgE-dependent mast-cell exocytosis | Q35751914 | ||
| FcepsilonR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells | Q35849299 | ||
| Silica-directed mast cell activation is enhanced by scavenger receptors | Q35855252 | ||
| Mast cells in the development of adaptive immune responses | Q36015885 | ||
| c-kit ligand: a unique potentiator of mediator release by human lung mast cells | Q36230802 | ||
| Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor | Q36287291 | ||
| Integrated signalling pathways for mast-cell activation | Q36392833 | ||
| Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production | Q36400671 | ||
| Anaphylaxis: clinical concepts and research priorities. | Q36466735 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mast cell | Q191989 |
| P304 | page(s) | 128-138 | |
| P577 | publication date | 2007-10-09 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation | |
| P478 | volume | 324 |
| Q34476441 | Adapters in the organization of mast cell signaling |
| Q37259631 | Amplification mechanisms for the enhancement of antigen-mediated mast cell activation |
| Q54530121 | Anti-allergic effects of nilotinib on mast cell-mediated anaphylaxis like reactions |
| Q42665868 | Assessing anaphylactic risk? Consider mast cell clonality |
| Q27332182 | CADM1 controls actin cytoskeleton assembly and regulates extracellular matrix adhesion in human mast cells |
| Q33811207 | Chiral kinase inhibitors |
| Q33358546 | Effect of lipopolysaccharide (LPS) and peptidoglycan (PGN) on human mast cell numbers, cytokine production, and protease composition |
| Q34073540 | Generation, isolation, and maintenance of human mast cells and mast cell lines derived from peripheral blood or cord blood. |
| Q34214029 | Glycogen synthase kinase 3beta activation is a prerequisite signal for cytokine production and chemotaxis in human mast cells |
| Q35680494 | Lipoxin B₄ promotes the resolution of allergic inflammation in the upper and lower airways of mice |
| Q42177446 | Mast cell chemotaxis - chemoattractants and signaling pathways |
| Q34017091 | Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype |
| Q34572441 | Modulation of mast cell proliferative and inflammatory responses by leukotriene d4 and stem cell factor signaling interactions |
| Q24603534 | Narrative review: the systemic capillary leak syndrome |
| Q36842503 | Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders |
| Q26748784 | Pharmacological treatment options for mast cell activation disease |
| Q38068961 | Role of mast cells in mucosal diseases: current concepts and strategies for treatment |
| Q38737251 | Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events |
| Q54497833 | Targeting c-kit in the therapy of mast cell disorders: Current update |
| Q36487624 | Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation |
| Q37848482 | Tec family kinases: regulation of FcεRI-mediated mast-cell activation |
| Q37158872 | The tyrosine kinase network regulating mast cell activation |
| Q34812522 | Total synthesis of LL-Z1640-2 utilizing a late-stage intramolecular Nozaki–Hiyama–Kishi reaction |
| Q34035784 | Twenty-first century mast cell stabilizers. |
| Q54558599 | Tyrosine kinase inhibitor sunitinib relieves systemic and oral antigen-induced anaphylaxes in mice |
Search more.